PL3041472T3 - Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiego - Google Patents
Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiegoInfo
- Publication number
- PL3041472T3 PL3041472T3 PL15763622T PL15763622T PL3041472T3 PL 3041472 T3 PL3041472 T3 PL 3041472T3 PL 15763622 T PL15763622 T PL 15763622T PL 15763622 T PL15763622 T PL 15763622T PL 3041472 T3 PL3041472 T3 PL 3041472T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- multiple myeloma
- quinoline carboxamides
- carboxamides
- quinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185892 | 2014-09-23 | ||
| EP15763622.6A EP3041472B1 (en) | 2014-09-23 | 2015-09-18 | Quinoline carboxamides for use in the treatment of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3041472T3 true PL3041472T3 (pl) | 2017-08-31 |
Family
ID=51660309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15763622T PL3041472T3 (pl) | 2014-09-23 | 2015-09-18 | Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiego |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956212B2 (pl) |
| EP (1) | EP3041472B1 (pl) |
| JP (1) | JP6647287B2 (pl) |
| KR (1) | KR102533033B1 (pl) |
| CN (1) | CN107108510B (pl) |
| AU (1) | AU2015316824B2 (pl) |
| CA (1) | CA2961978C (pl) |
| EA (1) | EA030948B1 (pl) |
| ES (1) | ES2631194T3 (pl) |
| IL (1) | IL251043B (pl) |
| MX (1) | MX366837B (pl) |
| NZ (1) | NZ730816A (pl) |
| PL (1) | PL3041472T3 (pl) |
| WO (1) | WO2016042112A1 (pl) |
| ZA (1) | ZA201702377B (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015316824B2 (en) * | 2014-09-23 | 2020-10-29 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
| EP4114368A1 (en) * | 2020-03-03 | 2023-01-11 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| CN116782902A (zh) | 2020-07-23 | 2023-09-19 | 伊拉兹马斯大学鹿特丹医学中心 | 作为骨髓增殖性肿瘤中的新治疗靶标的s100蛋白 |
| US20240091215A1 (en) | 2021-01-18 | 2024-03-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| IL308542A (en) | 2021-05-25 | 2024-01-01 | Active Biotech Ab | Multiparticles of tesquinimod and their use |
| WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| RS51019B (sr) * | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| JP2013526852A (ja) * | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
| CA2802006C (en) | 2010-07-09 | 2018-09-25 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| WO2012024543A1 (en) * | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| WO2012034543A1 (es) | 2010-09-13 | 2012-03-22 | Universidad De Costa Rica | Conector estructural para bambú |
| FR2967353B1 (fr) * | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| AU2015316824B2 (en) * | 2014-09-23 | 2020-10-29 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
-
2015
- 2015-09-18 AU AU2015316824A patent/AU2015316824B2/en active Active
- 2015-09-18 CA CA2961978A patent/CA2961978C/en active Active
- 2015-09-18 KR KR1020177010510A patent/KR102533033B1/ko active IP Right Grant
- 2015-09-18 EA EA201790687A patent/EA030948B1/ru not_active IP Right Cessation
- 2015-09-18 EP EP15763622.6A patent/EP3041472B1/en active Active
- 2015-09-18 JP JP2017513751A patent/JP6647287B2/ja active Active
- 2015-09-18 US US15/510,728 patent/US9956212B2/en active Active
- 2015-09-18 CN CN201580051397.XA patent/CN107108510B/zh active Active
- 2015-09-18 PL PL15763622T patent/PL3041472T3/pl unknown
- 2015-09-18 NZ NZ730816A patent/NZ730816A/en unknown
- 2015-09-18 WO PCT/EP2015/071391 patent/WO2016042112A1/en active Application Filing
- 2015-09-18 MX MX2017003294A patent/MX366837B/es active IP Right Grant
- 2015-09-18 ES ES15763622.6T patent/ES2631194T3/es active Active
-
2017
- 2017-03-09 IL IL251043A patent/IL251043B/en active IP Right Grant
- 2017-04-04 ZA ZA2017/02377A patent/ZA201702377B/en unknown
-
2018
- 2018-04-06 US US15/947,279 patent/US10314836B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015316824B2 (en) | 2020-10-29 |
| CN107108510A (zh) | 2017-08-29 |
| ZA201702377B (en) | 2018-08-29 |
| MX366837B (es) | 2019-07-26 |
| ES2631194T3 (es) | 2017-08-29 |
| WO2016042112A1 (en) | 2016-03-24 |
| AU2015316824A1 (en) | 2017-04-27 |
| IL251043A0 (en) | 2017-04-30 |
| CA2961978C (en) | 2023-03-14 |
| US10314836B2 (en) | 2019-06-11 |
| NZ730816A (en) | 2022-01-28 |
| EA030948B1 (ru) | 2018-10-31 |
| IL251043B (en) | 2020-02-27 |
| CA2961978A1 (en) | 2016-03-24 |
| US9956212B2 (en) | 2018-05-01 |
| EP3041472B1 (en) | 2017-02-01 |
| MX2017003294A (es) | 2017-06-23 |
| BR112017004947A2 (pt) | 2017-12-05 |
| US20180228794A1 (en) | 2018-08-16 |
| KR102533033B1 (ko) | 2023-05-15 |
| EP3041472A1 (en) | 2016-07-13 |
| US20170273967A1 (en) | 2017-09-28 |
| KR20170052691A (ko) | 2017-05-12 |
| EA201790687A1 (ru) | 2017-08-31 |
| CN107108510B (zh) | 2020-10-23 |
| JP2017528473A (ja) | 2017-09-28 |
| JP6647287B2 (ja) | 2020-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249481A0 (en) | Difluoromethyl-indanyl-nicotinic carboxamides | |
| IL248856A0 (en) | New treatment | |
| HK1244485A1 (zh) | 用於治療神經母細胞瘤的組合物 | |
| ZA201702377B (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| HUE051924T2 (hu) | Hõkezelési eljárás | |
| GB201401430D0 (en) | Treatment process | |
| IL251904B (en) | Epilimod for use in the treatment of melanoma | |
| IL252174B (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| GB201416832D0 (en) | Methods of treatment | |
| SG11201702700UA (en) | Methods for the treatment of peri-implantitis | |
| HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
| GB201411027D0 (en) | Treatment | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201400311D0 (en) | Treating Susceptibility | |
| GB201418541D0 (en) | Materials for use with general hyperthermia treatment | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201417719D0 (en) | New treatment | |
| GB201408384D0 (en) | New treatment | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201412411D0 (en) | Treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201400235D0 (en) | Treatment | |
| GB201400241D0 (en) | Treatment | |
| GB201400239D0 (en) | Treatment | |
| GB201400240D0 (en) | Treatment |